UNICYCIVE THERAPEUTICS INC

UNCYNASDAQ

🏆 #2994 by market capEarnings Aug 12US Equity

$5.00▼ $0.02 (−0.40%)

🌙 After hours$5.11▲ 2.14%Regular close · extended-hours price shown

1h—

24h▼ 0.4%

7d—

14d—

30d—

1y—

🏦Market Cap

$134M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

No chart data available for UNCY.

Trading Snapshot

Day Range: $4.96 – $5.06
52-Week Range: $3.71 – $8.74
Volume: $4.34B
Avg Volume: $3.57B
Shares Outstanding: 26.7M
Next Earnings: Aug 31, 2026

Fundamentals Snapshot

Annual Revenue: $24M
Last Q Revenue: $6M
P/E Ratio: -2.4
P/S Ratio: 0.0x
EPS (TTM): $-0.17
Dividend Yield: 0.00%

Why Investors Own UNCY

✓High-growth profile — revenue up +4.7% YoY with expanding US Equity exposure.
✓Healthy economics — 37% gross margin and 23% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$24M▲ +9.5% YoY

Gross Margin (TTM)

37.4%▲ +3.4% YoY

Operating Income (TTM)

$5M▲ +9.5% YoY

Free Cash Flow (TTM)

$5M▲ +9.5% YoY

About UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

🦦